

Special Issue

The Molecular Mechanisms Underlying the Activation and Regulation of Signaling Pathways in Cancer

Message from the Guest Editor

Cancer is a complex and multifaceted disease, with signaling pathways playing a crucial role in its development and progression. In this Special Issue, we aim to explore the intricate molecular mechanisms that underlie the activation and regulation of signaling pathways in cancer. By bringing together a collection of high-quality contributions, this special Issue aims to advance our understanding of the molecular mechanisms underlying signaling pathway dysregulation in cancer and provide insights into potential therapeutic interventions. We welcome original research articles, reviews, and perspectives that delve into the molecular basis of signaling pathways in cancer, including, but not limited to, the following topics:

- Key signaling pathways implicated in cancer development and progression;
- Crosstalk and interactions between different signaling pathways in cancer cells;
- Post-translational modifications and their impact on signaling pathway activation in cancer;
- Molecular regulators and modulators of signaling pathway activity in cancer;
- Novel therapeutic targets and strategies based on signaling pathway dysregulation in cancer.

Guest Editor

Dr. Emanuele Giurisato

Department of Biotechnology Chemistry & Pharmacy, University of Siena, Siena, Italy

Deadline for manuscript submissions

closed (31 July 2025)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/188750

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).